Join Growin Stock Community!

Inmune bio, inc.INMB.US Overview

US StockHealthcare
(No presentation for INMB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

INMB AI Insights

INMB Overall Performance

INMB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INMB Recent Performance

3.49%

Inmune bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

INMB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

INMB Key Information

INMB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

INMB Profile

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Price of INMB

INMB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

INMB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
685.90
PB Ratio
1.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-99774.00%
Revenue Growth (YoY)
19.05%
Profit Growth (YoY)
19.05%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
685.90
PB Ratio
1.40
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-99774.00%
Revenue Growth (YoY)
19.05%
Profit Growth (YoY)
19.05%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is INMB's latest earnings report released?

    The most recent financial report for Inmune bio, inc. (INMB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INMB's short-term business performance and financial health. For the latest updates on INMB's earnings releases, visit this page regularly.

  • How much debt does INMB have?

    As of the end of the reporting period, Inmune bio, inc. (INMB) had total debt of 1.08M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does INMB have?

    At the end of the period, Inmune bio, inc. (INMB) held Total Cash and Cash Equivalents of 27.73M, accounting for 0.83 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is INMB's EPS continuing to grow?

    According to the past four quarterly reports, Inmune bio, inc. (INMB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INMB?

    Inmune bio, inc. (INMB)'s Free Cash Flow (FCF) for the period is -5.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 19.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INMB?

    The latest valuation data shows Inmune bio, inc. (INMB) has a Price-To-Earnings (PE) ratio of -0.92 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.